Literature DB >> 9824649

Adhesion of tumoricidal eosinophils to MCA-38 colon adenocarcinoma cells involves protein tyrosine kinase activation and is diminished by elevated cyclic AMP in the effector cell.

R Taylor1, T D Lee, D W Hoskin.   

Abstract

Although eosinophils have been implicated in immune responses to certain types of tumors, the mechanisms of anti-tumor activity by eosinophils are poorly understood. We show here that mouse eosinophils kill allogeneic MCA-38 colon adenocarcinoma cells in the absence of specific anti-body. Eosinophil adhesion to MCA-38 monolayers occurred within 15 min and plateaued at 90 min. Although mouse eosinophils express alphaL (CD11a), alphaM (CD11b), and alpha4 (CD49d) integrin chains, blocking antibody studies revealed that these molecules are not involved in eosinophil binding to MCA-38 cells. Adhesion was also fibronectin-independent. Binding was inhibited when eosinophils, but not MCA-38 cells, were pretreated with methyl 2,5-dihydroxycinnamate (MDHC), a selective inhibitor of protein tyrosine kinases, or 8-Br-cAMP-Na, a cell-permeable cyclic AMP analogue. Adhesion was unaffected by calphostin C, a specific inhibitor of protein kinase C, and wortmannin, a selective inhibitor of phosphatidylinositol 3-kinases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824649     DOI: 10.3892/ijo.13.6.1305

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility.

Authors:  K Murata; M Kameyama; F Fukui; H Ohigashi; M Hiratsuka; Y Sasaki; T Kabuto; M Mukai; T Mammoto; H Akedo; O Ishikawa; S Imaoka
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 2.  A new dawn for eosinophils in the tumour microenvironment.

Authors:  Sharon Grisaru-Tal; Michal Itan; Amy D Klion; Ariel Munitz
Journal:  Nat Rev Cancer       Date:  2020-07-16       Impact factor: 60.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.